London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks tacly and Jatw for posting the articles.
After watching CEO’s interview on Bloomberg, I am wondering if similar programs have been made in local languages for the Chinese viewers. The story of developing Fruquintinib (first ever oncology therapy completely developed in China) should be a matter of pride to Chinese scientific field. Hope such achievements are highlighted in the media over there. If done so, might help to improve company’s popularity among general public as well as among investing community.
Interesting article. Thanks Jatw. Here is another research article from CMB International, giving Hutchmed a target price of HK$77.74 or £7.24
https://www.cmbi.com/article/5925.html?lang=cn
https://uk.finance.yahoo.com/news/analysis-chinas-biotech-sector-comes-230728570.html
Interesting article….CH cited at the end…..also name checks most of Hutchmeds Chinese collaborators innovent, junshi, Beigene.
Hopefully this will help a bit with exposure:- Shanghai Observer news report about Hutchmed receiving an award
https://translate.google.com/translate?sl=zh-CN&tl=en&u=https://www.jfdaily.com/sgh/detail?id%3D539431
In the article, Cui Yixuan should be Yiling Cui - Hutchmed Senior Vice President, Government Affairs
Bit surprised with the lack of support in the market. Investors over there might be having multiple choices for investment.
Yes, volume of trading shown on HKEX official site doesn’t support any significant trading across the connect link.
This trend could be changed with some headline grabbing news such as commercial success with the 3 drugs already in the market and/or, further collaborations with major players in the field.
I don’t know if it possible to see the trading of HCM on the connect platform? I did a basic search on HKEX but nothing stood out to me.
I guess it is like anything today, the market needs something new or a story to move the price. I suspect mainland Chinese will buy in gradually….I doubt LKS and 0013 mean as much as they did in HK.
I don’t know if the recent weakness is due to others success….eg Beigene has a drug accepted in the US for marginal zone lymphomas which is a similar area that 689 is targeting.
Yesterday’s announcement of a UK trial of a blood test to detect early signs of 50 cancers has to be good news for all oncology companies as earlier detection means more patients for longer….let’s hope that works out.
Thanks Jatw, for finding out the ‘reason for 40% fall in the sp’! Like everyone else, I too was scratching my head!!
Btw, recent inclusion of 13.HK to certain indexes and joining the ‘stock connect’ has not resulted in the anticipated response from the market. It might take some more time (and efforts) to receive attention of mainland investors and funds.
AW only posts to AVON (recently fell 40%) and HCM…..I conclude an accidental posting to the HCM aboard.
Source please?
Is the revenue fall related to the sale of the JV for USD170m? Or the timing of the AZ milestone payment following approval of Orpathys (this would be 25m)
SP falls c40% when Revenue guidance for the 12 months to 30 September 2021 is reduced to a range between $242 million and $260 million – the consensus estimate was for $277 million.
The pipeline is getting stronger, with exciting developments announced on 4 products over the last few weeks that will land in 2023/24.
While there is still lots of risk in new developments they carry little weight in today’s valuation.
I am confident that he best days lie ahead……
I’ll post the exact words from the H1 results discussion later, but analyst forecast is revs of just over$1bn by 2025 which suggests any cap of $25-30bn is realistic and perfectly possible
How much specifically by 2025? So you have an exact figure? Would be helpful.
Looking at the rapid pipeline and regulatory progress it’s easy to see why our CEO remains confident Hutchmed will be a very large Company by 2025. Today’s valuation will seem very small by then. Looking at Beigene and Gennab, two of my favourite peers, you can see how a company can grow from $5bn to $30bn within a few years as the pipeline commercialises
It seems they are on top of regulatory interactions as evidenced by today’s RNS of the China breakthrough treatment designation for 689 which is accelerating rapidly..sounds like another NDA in late 22/ early 23 and launch in mid to late 23? The timing should be clearer with the next FY results…
Thanks for posting, Davey.
CEO sounds extremely confident in answering questions and in explaining how Hutchmed is making progress in the sector. It is indeed pleasing to hear that HCM is one among very few China based pharmaceutical companies getting recognition in USA.